- Home
- Equipment
- netherlands
- therapeutic potential
Show results for
Refine by
Therapeutic Potential Equipment Supplied In Netherlands
6 equipment items found
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Accessing a new repertoire of targets. Two classes of molecule with therapeutic potential that are not currently addressed by antibody drugs are G-protein-coupled receptors and ion channels, largely because they display small epitopes not accessible to traditional antibodies and their sequence is often conserved and thus less likely to be ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases.1 Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death4,5 and even ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
In our Phase 1 clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. We believe the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...